Objectives
Study trends in the treatment of atrial septal defects (ASD).
Background
Concern for device erosion following transcatheter treatment of ASD (TC-ASD) led in 2012 to a US FDA panel review and changes in the instructions for use (IFU) of the Amplatzer Septal Occluder (ASO) device. No studies have assessed the effect of these changes on real-world practice.
Methods
A retrospective observational study was performed using data from the Pediatric Health Information Systems Database of all patients with isolated ASD undergoing either TC-ASD or operative ASD closure (O-ASD) from 1/1/2007 to 9/30/2015, hypothesizing that the propensity to pursue O-ASD increased beginning in 2013.
Results
6,392 cases from 39 centers underwent ASD closure (82% TC-ASD). Adjusting for patient factors, between 2007 and 2012, the probability of pursuing O-ASD decreased (OR: 0.95 per year, p=0.03). This trend reversed beginning in 2013, with the probability of O-ASD increasing annually (OR: 1.21, p=0.006). There was significant between-hospital variation in the choice between TC-ASD and O-ASD (median odds ratio: 2.79, p<0.0001). The age of patients undergoing ASD closure (regardless of method) decreased over the study period (p=0.04). Cost of O-ASD increased over the study period, while cost of TC-ASD and LOS for both O-ASD and TC-ASD was unchanged.
Conclusion
Though TC-ASD remains the predominant method of ASD closure, the propensity to pursue O-ASD has increased significantly following changes in IFU for ASO. Further research is necessary to determine what effect this has on outcomes and resource utilization.